Tempest Therapeutics Inc (TPST)

$7.76 +1.33 (20.59%)
Market Cap 28.58M
Revenue (ttm) 0.00
Net Income (ttm) -41.84M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 342,500
Avg Vol 139,258
Day's Range N/A - N/A
Shares Out 3.68M
Stochastic %K 100%
Beta -1.95
Analysts Sell
Price Target $9.00

Company Profile

Tempest Therapeutics, Inc., a clinical-stage biotechnology company, develops small molecule therapeutics to treat cancer. Its clinical-stage lead product candidates include Amezalpat, an oral small molecule selective antagonist of peroxisome proliferator-activated receptor alpha for the treatment of first-line unresectable or metastatic hepatocellular carcinoma; and TPST-1495, a small-molecule dual antagonist of the EP2 and EP4 receptors of prostaglandin E2 for treating various cancers. The comp...

Industry: Biotechnology
Sector: Healthcare
Phone: 415 798 8589
Address:
2000 Sierra Point Parkway, Suite 400, Brisbane, United States
Michl2000
Michl2000 Jul. 28 at 3:53 PM
$TPST Somebody loading at 8.22$ ???
1 · Reply
WitchKingOfAngmar
WitchKingOfAngmar Jul. 28 at 3:24 PM
$TPST I've always been enamored with this company. Got no clue why, but I've watched it along time. Looks ready for another wave up. Last wave was short and sweet. But did not last long. What about this one. It's a journey always. Just maybe it's an echo of the big red candle. Can it reach that last high? If it does, it goes higher. I think it see 11 anyway, than see. Lot of resistance there going back to Feb. Techs look really strong here going back to the 4-7 low with a positive divergence on MACD. Wanna take a ride?
1 · Reply
WallStreetIsNotEasy
WallStreetIsNotEasy Jul. 28 at 2:56 PM
$TPST my friend said it best right here 🎯
0 · Reply
Michl2000
Michl2000 Jul. 28 at 2:56 PM
$TPST again to the ones that are afraid this is only pump ;-)
0 · Reply
Rasco
Rasco Jul. 28 at 2:48 PM
$TPST just added again, near the HOD….
0 · Reply
GreenField2021
GreenField2021 Jul. 28 at 2:46 PM
$TPST the company is on sale. Market cap is less than $35 Million. However, TPST still has around 20 million cash and no employees, no debt. Now you can tell me if the share price is under value or not.
1 · Reply
Kels_11
Kels_11 Jul. 28 at 2:38 PM
$TPST 💥 or bust with this one!! More than willing to wait... what did Brady call the drug? "Blockbuster" I believe. So I'll hold for that Blockbuster deal.
0 · Reply
WallStreetIsNotEasy
WallStreetIsNotEasy Jul. 28 at 2:38 PM
$TPST up to 25k now gonna continue to add below 100 million cap
0 · Reply
CAN_2409
CAN_2409 Jul. 28 at 2:33 PM
$TPST ... CADL
0 · Reply
Heroforest
Heroforest Jul. 28 at 2:24 PM
$TPST I said earlier that if TIGIT failed in HCC, buy like there is no tomorrow. I think it’s now worth the bet!… still huge risk ahead, but the odds are in our favour remember that Roche agrees to supply atezo for free for TPST’s phase 3 trail so they are clearly interested. The price they willing to pay it wildly unknown, the poison pill makes it unknown…once the pill expire in October this year, market will decide where it should go. Roche may just hostile take over the company after October if the price can’t be agreed by both party.. Interesting time…
1 · Reply
Latest News on TPST
Tempest Receives Clearance to Proceed with Pivotal Trial of Amezalpat Combination Therapy for First-Line HCC in China

Jun 30, 2025, 8:00 AM EDT - 4 weeks ago

Tempest Receives Clearance to Proceed with Pivotal Trial of Amezalpat Combination Therapy for First-Line HCC in China

Tempest Announces $4.6 Million Registered Direct Offering of Common Stock

Jun 11, 2025, 8:00 AM EDT - 6 weeks ago

Tempest Announces $4.6 Million Registered Direct Offering of Common Stock

Tempest Receives Orphan Drug Designation from the European Medicines Agency for Amezalpat for the Treatment of Patients with HCC

Jun 5, 2025, 8:00 AM EDT - 7 weeks ago

Tempest Receives Orphan Drug Designation from the European Medicines Agency for Amezalpat for the Treatment of Patients with HCC

Tempest Reports First Quarter 2025 Financial Results and Provides Business Update

May 13, 2025, 4:28 PM EDT - 2 months ago

Tempest Reports First Quarter 2025 Financial Results and Provides Business Update

Tempest Presents New Amezalpat MOA Data Reinforcing Its Potential as Novel Cancer Treatment at the 2025 AACR Annual Meeting

Apr 28, 2025, 4:05 PM EDT - 3 months ago

Tempest Presents New Amezalpat MOA Data Reinforcing Its Potential as Novel Cancer Treatment at the 2025 AACR Annual Meeting

Tempest Receives Orphan Drug Designation from the FDA for TPST-1495 to Treat Patients with FAP

Apr 21, 2025, 8:00 AM EDT - 3 months ago

Tempest Receives Orphan Drug Designation from the FDA for TPST-1495 to Treat Patients with FAP

Tempest Announces Plan to Explore Strategic Alternatives to Advance Promising Pipeline of Clinical Oncology Assets and Maximize Stockholder Value

Apr 9, 2025, 4:30 PM EDT - 3 months ago

Tempest Announces Plan to Explore Strategic Alternatives to Advance Promising Pipeline of Clinical Oncology Assets and Maximize Stockholder Value

Tempest Reports Year End 2024 Financial Results and Provides Business Update

Mar 27, 2025, 4:10 PM EDT - 4 months ago

Tempest Reports Year End 2024 Financial Results and Provides Business Update

Tempest Announces Amezalpat Poster Presentation at the 2025 American Association for Cancer Research (AACR) Annual Meeting

Mar 25, 2025, 4:30 PM EDT - 4 months ago

Tempest Announces Amezalpat Poster Presentation at the 2025 American Association for Cancer Research (AACR) Annual Meeting

FDA Study May Proceed Notice Received for Phase 2 Trial of TPST-1495 for the Treatment of Familial Adenomatous Polyposis (FAP)

Mar 13, 2025, 8:00 AM EDT - 4 months ago

FDA Study May Proceed Notice Received for Phase 2 Trial of TPST-1495 for the Treatment of Familial Adenomatous Polyposis (FAP)

Tempest Granted Fast Track Designation from the U.S. Food and Drug Administration for Amezalpat to Treat Patients with Hepatocellular Carcinoma

Feb 10, 2025, 8:00 AM EST - 6 months ago

Tempest Granted Fast Track Designation from the U.S. Food and Drug Administration for Amezalpat to Treat Patients with Hepatocellular Carcinoma

Tempest Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Feb 7, 2025, 4:30 PM EST - 6 months ago

Tempest Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Tempest Receives Orphan Drug Designation from the U.S. Food and Drug Administration for Amezalpat to Treat Patients with Hepatocellular Carcinoma (HCC)

Jan 6, 2025, 8:00 AM EST - 7 months ago

Tempest Receives Orphan Drug Designation from the U.S. Food and Drug Administration for Amezalpat to Treat Patients with Hepatocellular Carcinoma (HCC)

Tempest to Participate in the Piper Sandler 36th Annual Healthcare Conference

Nov 25, 2024, 4:30 PM EST - 8 months ago

Tempest to Participate in the Piper Sandler 36th Annual Healthcare Conference

Tempest Reports Third Quarter 2024 Financial Results and Provides Business Update

Nov 12, 2024, 4:21 PM EST - 9 months ago

Tempest Reports Third Quarter 2024 Financial Results and Provides Business Update

Why Is Cancer Focused Tempest Therapeutics Stock Trading Higher On Thursday?

Oct 10, 2024, 9:06 AM EDT - 10 months ago

Why Is Cancer Focused Tempest Therapeutics Stock Trading Higher On Thursday?

Tempest Announces Agreement with Roche to Support Advancement of Amezalpat Combination Therapy into First-Line Hepatocellular Carcinoma Pivotal Trial

Oct 10, 2024, 7:01 AM EDT - 10 months ago

Tempest Announces Agreement with Roche to Support Advancement of Amezalpat Combination Therapy into First-Line Hepatocellular Carcinoma Pivotal Trial

Tempest Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Sep 20, 2024, 4:30 PM EDT - 11 months ago

Tempest Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Tempest to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Sep 5, 2024, 8:00 AM EDT - 11 months ago

Tempest to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Tempest Announces Successful End-of-Phase 2 Meeting with FDA for Amezalpat (TPST-1120) to Treat First-Line Hepatocellular Carcinoma

Aug 15, 2024, 8:00 AM EDT - 1 year ago

Tempest Announces Successful End-of-Phase 2 Meeting with FDA for Amezalpat (TPST-1120) to Treat First-Line Hepatocellular Carcinoma

Tempest Reports Second Quarter 2024 Financial Results and Provides Business Update

Aug 8, 2024, 4:56 PM EDT - 1 year ago

Tempest Reports Second Quarter 2024 Financial Results and Provides Business Update

What's Going On With Cancer-Focused Tempest Therapeutics Stock On Thursday?

Jun 20, 2024, 9:43 AM EDT - 1 year ago

What's Going On With Cancer-Focused Tempest Therapeutics Stock On Thursday?

Tempest to Report New Data from Global Randomized Combination Study of Amezalpat (TPST-1120) in First-Line Hepatocellular Carcinoma

Jun 18, 2024, 6:22 PM EDT - 1 year ago

Tempest to Report New Data from Global Randomized Combination Study of Amezalpat (TPST-1120) in First-Line Hepatocellular Carcinoma

Glancy Prongay & Murray LLP Announces Investigation of Tempest Therapeutics, Inc. (TPST)

May 31, 2024, 3:45 PM EDT - 1 year ago

Glancy Prongay & Murray LLP Announces Investigation of Tempest Therapeutics, Inc. (TPST)

Tempest Reports First Quarter 2024 Financial Results and Provides Business Update

May 9, 2024, 4:29 PM EDT - 1 year ago

Tempest Reports First Quarter 2024 Financial Results and Provides Business Update

Tempest Therapeutics: Multiple 2024 Catalysts Make This A Must Watch

Apr 17, 2024, 1:26 PM EDT - 1 year ago

Tempest Therapeutics: Multiple 2024 Catalysts Make This A Must Watch

Tempest Reports New Preclinical Data for TPST-1120 in RCC at the AACR Annual Meeting

Apr 9, 2024, 8:00 AM EDT - 1 year ago

Tempest Reports New Preclinical Data for TPST-1120 in RCC at the AACR Annual Meeting

Tempest Announces Publication of Positive Data from Phase 1 Trial of TPST-1120 in Patients with Advanced Solid Tumors in Journal of Cancer Research Communications

Apr 4, 2024, 8:00 AM EDT - 1 year ago

Tempest Announces Publication of Positive Data from Phase 1 Trial of TPST-1120 in Patients with Advanced Solid Tumors in Journal of Cancer Research Communications

Tempest Reports Year End 2023 Financial Results and Provides Business Update

Mar 19, 2024, 4:25 PM EDT - 1 year ago

Tempest Reports Year End 2023 Financial Results and Provides Business Update

Tempest Announces Upcoming Presentation of Preclinical Data for TPST-1120 in Renal Cell Carcinoma at the AACR Annual Meeting

Mar 5, 2024, 4:30 PM EST - 1 year ago

Tempest Announces Upcoming Presentation of Preclinical Data for TPST-1120 in Renal Cell Carcinoma at the AACR Annual Meeting

Tempest to Present at the 35th Annual Piper Sandler Healthcare Conference

Nov 20, 2023, 8:00 AM EST - 1 year ago

Tempest to Present at the 35th Annual Piper Sandler Healthcare Conference

Tempest Reports Third Quarter 2023 Financial Results and Provides Business Update

Nov 8, 2023, 5:17 PM EST - 1 year ago

Tempest Reports Third Quarter 2023 Financial Results and Provides Business Update

Tempest Therapeutics shares end wild week with 8% drop

Oct 13, 2023, 4:13 PM EDT - 1 year ago

Tempest Therapeutics shares end wild week with 8% drop

Tempest Therapeutics shares head back to earth after 4,000% gain

Oct 12, 2023, 12:49 PM EDT - 1 year ago

Tempest Therapeutics shares head back to earth after 4,000% gain

Top trending biotech stocks: ANVS, MTNB, AVTX, TPST

Oct 12, 2023, 11:26 AM EDT - 1 year ago

Top trending biotech stocks: ANVS, MTNB, AVTX, TPST

ANVS AVTX MTNB

Tempest Therapeutics' stock jumps 1,900% as liver-cancer treatment shows promise

Oct 11, 2023, 12:29 PM EDT - 1 year ago

Tempest Therapeutics' stock jumps 1,900% as liver-cancer treatment shows promise

Tempest Adopts Limited Duration Stockholder Rights Plan

Oct 11, 2023, 8:01 AM EDT - 1 year ago

Tempest Adopts Limited Duration Stockholder Rights Plan

Tempest Releases New Data Demonstrating Superiority of TPST-1120 Arm Across Multiple Study Endpoints in Randomized First-Line HCC Study

Oct 11, 2023, 8:00 AM EDT - 1 year ago

Tempest Releases New Data Demonstrating Superiority of TPST-1120 Arm Across Multiple Study Endpoints in Randomized First-Line HCC Study

Tempest to Report New and Updated Data from Global Randomized Combination Study of TPST-1120 in First-Line Hepatocellular Carcinoma

Oct 10, 2023, 4:05 PM EDT - 1 year ago

Tempest to Report New and Updated Data from Global Randomized Combination Study of TPST-1120 in First-Line Hepatocellular Carcinoma

Tempest Announces Expanded Role for Sam Whiting, M.D., Ph.D., as Chief Medical Officer and Head of Research and Development

Sep 19, 2023, 8:00 AM EDT - 2 years ago

Tempest Announces Expanded Role for Sam Whiting, M.D., Ph.D., as Chief Medical Officer and Head of Research and Development

Tempest Reports Second Quarter 2023 Financial Results and Provides Business Update

Aug 10, 2023, 4:13 PM EDT - 2 years ago

Tempest Reports Second Quarter 2023 Financial Results and Provides Business Update

Tempest to Present at the Jefferies Global Healthcare Conference

May 31, 2023, 4:05 PM EDT - 2 years ago

Tempest to Present at the Jefferies Global Healthcare Conference

Tempest to Present Phase 1 Monotherapy and Combination Data at ASCO for TPST-1495 in Patients with Advanced Cancers

May 25, 2023, 5:00 PM EDT - 2 years ago

Tempest to Present Phase 1 Monotherapy and Combination Data at ASCO for TPST-1495 in Patients with Advanced Cancers

Tempest Reports First Quarter 2023 Financial Results and Provides Business Update

May 10, 2023, 4:15 PM EDT - 2 years ago

Tempest Reports First Quarter 2023 Financial Results and Provides Business Update

Tempest to Report Early Results from Global Randomized Phase 1b/2 Combination Study of TPST-1120 in First-Line Hepatocellular Carcinoma

Apr 27, 2023, 4:58 PM EDT - 2 years ago

Tempest to Report Early Results from Global Randomized Phase 1b/2 Combination Study of TPST-1120 in First-Line Hepatocellular Carcinoma

Tempest Announces TPST-1495 Poster Presentation at the 2023 ASCO Annual Meeting

Apr 26, 2023, 6:41 PM EDT - 2 years ago

Tempest Announces TPST-1495 Poster Presentation at the 2023 ASCO Annual Meeting

Tempest Reports Year End 2022 Financial Results and Provides Business Update

Mar 22, 2023, 5:26 PM EDT - 2 years ago

Tempest Reports Year End 2022 Financial Results and Provides Business Update

Tempest to Present New Translational and Preclinical Data at the 2023 AACR Annual Meeting

Mar 14, 2023, 4:30 PM EDT - 2 years ago

Tempest to Present New Translational and Preclinical Data at the 2023 AACR Annual Meeting

Tempest to Present at the Piper Sandler 34th Annual Healthcare Conference

Nov 22, 2022, 4:05 PM EST - 2 years ago

Tempest to Present at the Piper Sandler 34th Annual Healthcare Conference

Tempest Reports Third Quarter 2022 Financial Results and Provides Business Update

Nov 8, 2022, 8:00 AM EST - 2 years ago

Tempest Reports Third Quarter 2022 Financial Results and Provides Business Update

Michl2000
Michl2000 Jul. 28 at 3:53 PM
$TPST Somebody loading at 8.22$ ???
1 · Reply
WitchKingOfAngmar
WitchKingOfAngmar Jul. 28 at 3:24 PM
$TPST I've always been enamored with this company. Got no clue why, but I've watched it along time. Looks ready for another wave up. Last wave was short and sweet. But did not last long. What about this one. It's a journey always. Just maybe it's an echo of the big red candle. Can it reach that last high? If it does, it goes higher. I think it see 11 anyway, than see. Lot of resistance there going back to Feb. Techs look really strong here going back to the 4-7 low with a positive divergence on MACD. Wanna take a ride?
1 · Reply
WallStreetIsNotEasy
WallStreetIsNotEasy Jul. 28 at 2:56 PM
$TPST my friend said it best right here 🎯
0 · Reply
Michl2000
Michl2000 Jul. 28 at 2:56 PM
$TPST again to the ones that are afraid this is only pump ;-)
0 · Reply
Rasco
Rasco Jul. 28 at 2:48 PM
$TPST just added again, near the HOD….
0 · Reply
GreenField2021
GreenField2021 Jul. 28 at 2:46 PM
$TPST the company is on sale. Market cap is less than $35 Million. However, TPST still has around 20 million cash and no employees, no debt. Now you can tell me if the share price is under value or not.
1 · Reply
Kels_11
Kels_11 Jul. 28 at 2:38 PM
$TPST 💥 or bust with this one!! More than willing to wait... what did Brady call the drug? "Blockbuster" I believe. So I'll hold for that Blockbuster deal.
0 · Reply
WallStreetIsNotEasy
WallStreetIsNotEasy Jul. 28 at 2:38 PM
$TPST up to 25k now gonna continue to add below 100 million cap
0 · Reply
CAN_2409
CAN_2409 Jul. 28 at 2:33 PM
$TPST ... CADL
0 · Reply
Heroforest
Heroforest Jul. 28 at 2:24 PM
$TPST I said earlier that if TIGIT failed in HCC, buy like there is no tomorrow. I think it’s now worth the bet!… still huge risk ahead, but the odds are in our favour remember that Roche agrees to supply atezo for free for TPST’s phase 3 trail so they are clearly interested. The price they willing to pay it wildly unknown, the poison pill makes it unknown…once the pill expire in October this year, market will decide where it should go. Roche may just hostile take over the company after October if the price can’t be agreed by both party.. Interesting time…
1 · Reply
WallStreetIsNotEasy
WallStreetIsNotEasy Jul. 28 at 2:24 PM
$TPST the only way they keep this down is illegal naked shorting and dark pools. They don’t understand the volume that is coming tho and won’t be able to control it much longer. Don’t let them fool you WE are going much higher
1 · Reply
zambono
zambono Jul. 28 at 2:23 PM
$TPST still alive I see, call me when we are back around $12
0 · Reply
HectorNumba9
HectorNumba9 Jul. 28 at 2:21 PM
$TPST fuck me do we average up🤦🏽‍♂?
0 · Reply
topstockalerts
topstockalerts Jul. 28 at 2:18 PM
$TPST she wants to move higher..
0 · Reply
PRiZZo_74Breeze_X
PRiZZo_74Breeze_X Jul. 28 at 2:06 PM
$TPST WKSP active tape 🟢 Buyers absorbing ahead of key $4 breakout zone. Momentum building
0 · Reply
sanabu
sanabu Jul. 28 at 2:05 PM
$TPST no news of buyout or mergee ,just rumours ?
1 · Reply
WallStreetIsNotEasy
WallStreetIsNotEasy Jul. 28 at 2:03 PM
$TPST added on the 7’s
0 · Reply
dan4100
dan4100 Jul. 28 at 2:02 PM
$TPST Currently approaching the avg daily volume already.
0 · Reply
sr345
sr345 Jul. 28 at 1:59 PM
$TPST Anyone who has a fraction of intellect and knows the basics of markets realises that the price dip right now is merely from people closing their trades that they opened on Friday. When a stock trends like this did on Friday, it brings a lot of traders. Just as I typed this the price bounced from $7.70 to $8.10 😂😂😂. This is going to $100 P/S minimum real soon.
0 · Reply
GLD
GLD Jul. 28 at 1:46 PM
$TPST The more everyone buys, the more the management may sell. To me, this seems to be a stock printing machine operated by mosquito authority, junk island and bankrupt stock alerts. Whenever they appear on this board, be careful. If you do not understand the comments, you are most likely to lose money. Not a financial advisor and all in my opinion of course.
1 · Reply
bigboyycizzla
bigboyycizzla Jul. 28 at 1:44 PM
$TPST last dip before the rip
0 · Reply